Journal of Clinical Oncology
Articles in this Issue
Successful induction of tumor-directed immune responses in high grade serious ovarian carcinoma patients after primary treatment using a whole tumor cell vaccine.
5566 Background: Improving disease free and overall survival in advanced high grade serous ovarian carcinoma (HGSOC) after primary treatment remains chall...
Multidimensional, spatially resolved immunologic hallmarks of response to neoadjuvant immune checkpoint blockade (ICB) therapies.
9562 Background: The groundbreaking neoadjuvant ICB clinical trials have established beyond doubt that ICB before surgery will become the new standard of...
Peripheral myeloid-derived suppressor cell as a biomarker for diagnosing and predicting the treatment efficacy of colorectal cancer.
e15535 Background: Colorectal cancer (CRC) is one of the most common malignant tumors in the world. The myeloid-derived suppressor cells (MDSCs) are major...
A two-decade review of thyroid cancer mortality among older adults in the U.S.
e18153 Background: Thyroid cancer is the fourth leading cause of cancer-related deaths worldwide and the fifth in the United States. Although its incidenc...
A phase 1/2 study of JK06, a 5T4 antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer.
TPS3182 Background: 5T4, a Type I transmembrane glycoprotein, plays a pivotal role in neonatal development, but its expression in normal adult tissues is...
Updated results from a phase II study of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104) for HER2-expressing muscle-invasive bladder cancer (MIBC).
4588 Background: Several current ongoing clinical trials have shown promising efficacy and safety of antibody-drug conjugates (ADCs) alone and in combinat...
Proton pump inhibitors and the risk of adverse renal events and all-cause mortality in cancer patients receiving immune checkpoint inhibitors.
11173 Background: Immune checkpoint inhibitors (ICI) have transformed cancer treatment by improving prognosis across various malignancies, while proton pu...
Preliminary safety and efficacy data of ICP-248, a novel BCL2 inhibitor, in patients with relapsed or refractory B-cell malignancies.
7038 Background: BCL2, a critical protein regulator of the apoptotic pathway, highly expressed in various malignancies, including B-cell non-Hodgkin lymph...
Trends in incidence and five-year relative survival analysis of classical Hodgkin lymphoma in children, adolescents, and young adults (ages <20): A population-based study using National Childhood Cancer Registry (NCCR) data (2001–2021).
e13778 Background: Classical Hodgkin lymphoma (cHL) is a significant malignancy affecting pediatric populations, with implications for public health and c...
SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies.
TPS7083 Background: AZD0486 is an IgG4 fully human CD19xCD3 bispecific T-cell engager that binds CD3 with low affinity to potentially reduce cytokine rele...
Transforming kidney cancer treatment through AI-enabled functional precision medicine: The PEAR-TREE2 trial.
TPS4615 Background: Advanced renal cell carcinoma (RCC) presents a significant clinical challenge, with limited predictive biomarkers for treatment respon...
A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 ± niraparib in adults with advanced or metastatic solid tumors.
TPS3174 Background: In homologous recombination-deficient (HRd) tumors, use of a PARP inhibitor (PARPi) leads to generation of DNA breaks that cannot be e...
Tumor heterogeneity between primary and paired recurrent breast cancer and its potential molecular mechanism.
e13177 Background: Breast cancer serves as a type of highly heterogeneous tumor. Patients with heterogeneity between primary and recurrent breast tumors h...
Socioeconomic and clinical characteristics of large cell medulloblastoma: A comprehensive NCDB study.
e14040 Background: Large cell medulloblastoma (LCMB) is a rare and aggressive subtype of medulloblastoma, marked by large pleomorphic tumor cells typicall...
Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.
11507 Background: Advanced uterine leiomyosarcoma (uLMS) is an aggressive malignancy with poor prognosis. Standard-of-care treatments, including trabected...
Evaluating zAvatar test-guided chemotherapy vs. standard of care in relapsed ovarian cancer and metastatic breast cancer: A multicenter randomized clinical trial (zAVATAR-FLUIDS).
TPS5631 Background: Relapsed ovarian cancer and metastatic breast cancer (MBC) present significant challenges due to tumor heterogeneity and limited treat...
Automated clinical data extraction from oncology trials using large language models.
e13694 Background: Efficient access to structured clinical data is critical for decision making in oncology trials. However, manual extraction from unstru...
Melanoma mortality in Brazil: Insights from over 25 years of data and the impact of limited immunotherapy access in the public health system.
e22582 Background: Skin cancer is the most common cancer globally and in Brazil – and melanoma, its deadliest form. Despite advancements in Immunotherapy...
Circulating tumor DNA as a prognostic biomarker for long-term survival in de-novo oligometastatic non-small cell lung cancer.
e20535 Background: For patients with de-novo oligometastatic non-small cell lung cancer (NSCLC), combining local ablative therapy (LAT) with systemic trea...
Rational use of adjuvant anti-PD-1: Multi-omics model of recurrence in stage III melanoma.
9569 Background: Stage III melanoma patients (pts) undergoing adjuvant anti-PD-1 immunotherapy have a high risk of recurrence (43% within one year) and tr...
Enhancing clinical trial imaging workflow with AI integration.
e13662 Background: AI is revolutionizing clinical trials by assisting several stages of the trials, including patient recruitment, creation of clinical st...
A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (EBC) in China: Updated interim analysis from the NER-Tree study.
e12507 Background: Neratinib, a pan-HER tyrosine kinase inhibitor, was approved in China in 2020 based on the results of the ExteNET trial. With the incre...
Racial and ethnic disparities in US neuroendocrine tumor clinical trial enrollment over the past quarter century.
e16353 Background: Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms originating from neuroendocrine cells, with considerable variation...
Evaluating fairness and mitigating bias in models predicting financial toxicity among patients with genitourinary cancers.
1565 Background: Financial toxicity, the economic burden patients face from healthcare expenses, is a growing concern in cancer care. Recognizing the high...
HAI-score, an objective HER2 artificial intelligence method for accurate H-score estimation from IHC-stained breast cancer samples.
1116 Background: Accurate HER2 assessment is essential for breast cancer (BC) treatment, as it directs targeted therapy decisions and predicts patient pro...